Liraglutide Side Effects

Reported Liraglutide side effects

Everything below comes from human studies and the US labels unless it is marked as animal data. Gastrointestinal effects Nausea and diarrhea, mostly mild or moderate, were the most frequent adverse events with liraglutide 3.0 mg in the 3,731-person SCALE Obesity and Prediabetes trial, and serious adverse events occurred in 6.2 percent on liraglutide and 5.0 percent on placebo (PMID: 26132939). Against sitagliptin in type 2 diabetes, nausea affected 27 percent on liraglutide 1.8 mg, 21 percent on 1.2 mg and 5 percent on sitagliptin (PMID: 20417856). Against once-weekly exenatide in DURATION-6, nausea affected 21 percent on liraglutide and 9 percent on exenatide, diarrhea 13 and 6 percent, and vomiting 11 and 4 percent (PMID: 23141817). The Victoza label reports severe gastrointestinal adverse reactions in 4.4 percent (1.2 mg) and 4.2 percent (1.8 mg) of trial patients against 1.1 percent on placebo, and does not recommend liraglutide in severe gastroparesis (Victoza label). In adolescents in SCALE Teens, gastrointestinal adverse events affected 64.8 percent on liraglutide and 36.5 percent on placebo, and 10.4 percent stopped treatment because of adverse events against none on placebo (PMID: 32233338). In children aged 6 to under 12 in SCALE Kids, gastrointestinal adverse events affected 80 percent on liraglutide and 54 percent on placebo (PMID: 39258838). Pancreas LEADER recorded adjudicated acute pancreatitis in 18 people (0.4 percent) on liraglutide and 23 (0.5 percent) on placebo. Serum lipase rose 28 percent and amylase 7 percent with liraglutide compared with placebo, and these rises did not predict later pancreatitis (PMID: 28476871). Both US labels warn that acute pancreatitis (including fatal hemorrhagic or necrotizing cases) has been seen with GLP-1 receptor agonists including liraglutide (Victoza label; Saxenda label). Gallbladder In the adult Saxenda trials, cholelithiasis was reported in 2.2 percent on liraglutide and 0.8 percent on placebo, and cholecystitis in 0.8 and 0.4 percent (Saxenda label). Most affected patients on liraglutide needed cholecystectomy, and the excess remained after accounting for the amount of weight lost (Saxenda label). Thyroid The boxed warning rests on thyroid C-cell tumors in rats and mice; the labels state that the human relevance has not been determined and that postmarketing reports of medullary thyroid carcinoma in liraglutide users are insufficient to establish or exclude a causal link (Victoza label; Saxenda label). A 2024 cohort study across Denmark, Norway and Sweden compared 145,410 people starting a GLP-1 receptor agonist with 291,667 starting a DPP-4 inhibitor and found no increased risk of thyroid cancer over a mean 3.9 years (hazard ratio 0.93, 95 percent CI 0.66 to 1.31; for medullary thyroid cancer 1.19, 95 percent CI 0.37 to 3.86). The Scandinavian study covered GLP-1 receptor agonists as a class rather than liraglutide alone (PMID: 38683947). Heart rate Mean resting heart rate rose 2 to 3 beats per minute with Saxenda compared with placebo in adult trials, and more patients on liraglutide had rises of more than 10 beats per minute at two consecutive visits (34 percent against 19 percent) (Saxenda label). Low blood sugar Both US labels describe a higher risk of hypoglycemia (including severe hypoglycemia) when liraglutide is combined with insulin or an insulin secretagogue such as a sulfonylurea (Victoza label; Saxenda label). In the adolescent weight-management trial, clinically significant hypoglycemia (below 54 mg/dL) occurred in 1.6 percent on liraglutide and 0.8 percent on placebo, although none of the participants had type 2 diabetes (Saxenda label). In LEAD-6, minor hypoglycemia occurred in 25.5 percent on liraglutide and 33.6 percent on twice-daily exenatide, against a background of metformin, a sulfonylurea or both (PMID: 19515413). Adding liraglutide to insulin in 1,398 adults with type 1 diabetes raised the rate of symptomatic hypoglycemia, and hyperglycemia with ketosis rose with the 1.8 mg dose (rate ratio 2.22) (PMID: 27506222). Kidneys Postmarketing reports describe acute kidney injury, sometimes needing dialysis, mostly in patients dehydrated by nausea, diarrhea or vomiting (Victoza label). In LEADER, renal adverse events were similar on liraglutide and placebo (15.1 and 16.5 events per 1,000 patient-years); they included acute kidney injury at 7.1 and 6.2 events per 1,000 patient-years (PMID: 28854085). Suicidality In SCALE Teens, one participant on liraglutide died by suicide, an event the investigator judged unlikely to be related to the trial treatment (PMID: 32233338). According to the label's list of recent major changes, the warning on suicidal behavior and ideation was removed from the Saxenda label in February 2026 (Saxenda label). Other label warnings Both US labels list serious hypersensitivity reactions (including anaphylaxis and angioedema) from postmarketing reports, and pulmonary aspiration during general anesthesia or deep sedation reported with GLP-1 receptor agonists (Victoza label; Saxenda label). Pregnancy In pregnant rats and rabbits, liraglutide caused early embryonic deaths and fetal abnormalities at exposures close to or below those in people (animal data, Victoza label). In a 2026 Danish registry study, liraglutide exposure around conception for diabetes was linked to preterm birth (adjusted odds ratio 1.70), while exposure for weight management was not (adjusted odds ratio 1.01), and the authors suggested the underlying diabetes may explain the difference (PMID: 41852577). A 2026 meta-analysis of seven cohort studies with more than 40,000 exposed pregnancies found no statistically significant increase in congenital malformations with GLP-1 receptor agonists as a class (odds ratio 1.11), reported a signal for urinary malformations (odds ratio 1.24) that rested only on unadjusted data, and rated the certainty of evidence as low (PMID: 42420519).

When to continue, reduce, or stop Liraglutide

Liraglutide contraindications

The contraindications and cautions below are those stated in the US labels and trials, reported as the sources state them. Both US labels contraindicate liraglutide in people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2 (MEN 2) (Victoza label; Saxenda label). A previous serious hypersensitivity reaction to liraglutide or to an excipient is a contraindication on both labels (Victoza label; Saxenda label). Both labels say liraglutide is not recommended in severe gastroparesis (Victoza label; Saxenda label). As for a history of pancreatitis, the labels warn about acute pancreatitis with GLP-1 receptor agonists (Victoza label). In LEADER, the 147 people with previous pancreatitis who received liraglutide were not more likely to develop acute pancreatitis than the 120 similar people on placebo (PMID: 28476871). For other GLP-1 receptor agonists, the Saxenda label says combining it with other liraglutide-containing products or with any other GLP-1 receptor agonist is not recommended (Saxenda label). With insulin or sulfonylureas, the labels describe a higher risk of hypoglycemia (including severe hypoglycemia) (Victoza label). The Saxenda label says weight loss offers no benefit in pregnancy and may cause fetal harm, and that liraglutide should be stopped when a pregnancy is recognized; pregnancy itself was removed from the list of contraindications in May 2025 (Saxenda label). Animal studies showed embryo and fetal toxicity (Victoza label). For surgery and sedation, the labels report pulmonary aspiration in people taking GLP-1 receptor agonists during general anesthesia or deep sedation (Victoza label; Saxenda label). Acute kidney injury has been reported in people who became dehydrated from gastrointestinal side effects (Victoza label). In the ADJUNCT ONE trial in type 1 diabetes, liraglutide added to insulin increased symptomatic hypoglycemia and, at 1.8 mg, hyperglycemia with ketosis, which the authors said limits its clinical use in type 1 diabetes (PMID: 27506222). In the US, Victoza is labeled for type 2 diabetes from age 10 and Saxenda for weight management in adults and in adolescents aged 12 and older with obesity and body weight greater than 60 kg (Victoza label; Saxenda label).

Why vendor quality drives Liraglutide side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Liraglutide side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .